Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ETHACRYNIC ACID vs DEMADEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, potassium, and water. Also inhibits prostaglandin degradation.
Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Treatment of edema associated with congestive heart failure, cirrhosis, and renal disease,Treatment of ascites,Treatment of hypertension (off-label),Adjunctive therapy in acute pulmonary edema (off-label)
Edema associated with heart failure, hepatic cirrhosis, and renal disease,Hypertension (off-label)
50 to 100 mg orally once daily; may increase by 25 to 50 mg increments at intervals of 2 to 3 days up to 400 mg/day. IV: 0.5 to 1 mg/kg slowly (over several minutes); usual initial dose 50 mg.
Oral: 5-10 mg once daily; may increase to 20 mg once daily if needed. IV: 5-10 mg once daily; may increase to 20 mg once daily if needed. Maximum dose: 40 mg/day.
Terminal elimination half-life is approximately 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
The terminal elimination half-life is approximately 4 hours (range 2-8 hours) in patients with normal renal function. In renal impairment (creatinine clearance <30 m L/min), half-life is prolonged to 10-12 hours due to reduced renal clearance. In hepatic cirrhosis, half-life may be extended to 8-9 hours due to decreased metabolism.
Primarily metabolized by conjugation with glutathione; also undergoes hepatic metabolism via CYP450 enzymes (minor).
Primarily hepatic via CYP450 enzymes, with minimal renal clearance.
Primarily renal (approximately 60-70% as unchanged drug and metabolites) with some biliary/fecal excretion (approximately 30-40%).
Approximately 50% of the absorbed dose is excreted unchanged in the urine via glomerular filtration and active tubular secretion. The remainder undergoes hepatic metabolism to glucuronide conjugates and minor oxidative metabolites, with biliary excretion of metabolites (about 30-40% of the dose) eliminated in feces. Renal clearance is the primary route for the parent drug.
Approximately 90-98% bound to plasma proteins, primarily albumin.
Torsemide (DEMADEX) is extensively bound to plasma proteins, primarily albumin, with a protein binding of >99%.
Volume of distribution is approximately 0.1-0.2 L/kg, indicating limited extravascular distribution.
The apparent volume of distribution (Vd) is approximately 0.16 L/kg (range 0.12–0.20 L/kg), indicating distribution primarily within extracellular fluid. Vd is increased in conditions with expanded extracellular volume (e.g., heart failure, cirrhosis, nephrotic syndrome).
Oral bioavailability is approximately 100%.
Oral bioavailability is approximately 80–90%, with minimal first-pass metabolism. Absorption is rapid and not significantly affected by food.
e GFR 30-59 m L/min: no adjustment; e GFR <30 m L/min: avoid use due to risk of ototoxicity and decreased efficacy.
GFR <20 m L/min/1.73 m²: Use with caution; may require dose reduction or discontinuation due to accumulation. GFR 20-50: No adjustment needed. GFR >50: No adjustment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% or extend interval. Child-Pugh C: Avoid use or reduce dose by 75%.
Oral: 1 mg/kg/dose once daily; may increase by 1 mg/kg/dose at intervals of 2-3 days up to 3 mg/kg/day. IV: 1 mg/kg/dose slow IV; maximum 50 mg/dose.
Neonates and infants: 0.1-0.2 mg/kg/dose IV/IM once daily. Children: Oral: 0.5-1 mg/kg once daily; IV/IM: 0.1-0.2 mg/kg/dose once daily. Maximum: 5 mg/day.
Initiate at lower doses (25 mg orally once daily) due to increased risk of electrolyte disturbances and renal impairment; monitor closely.
Start at lower end of dose range (2.5-5 mg orally once daily); titrate slowly due to increased sensitivity and renal impairment risk.
This drug is a potent diuretic which, if given in excessive amounts, can lead to profound diuresis with water and electrolyte depletion. Close medical supervision and dose adjustment are required.
None.
Risk of excessive diuresis leading to dehydration, electrolyte imbalance, and hypovolemia,May cause ototoxicity, especially with rapid IV administration or in patients with renal impairment,Can worsen azotemia or precipitate hepatic encephalopathy in cirrhotic patients,Monitor serum electrolytes, CO2, BUN, and creatinine regularly,Use with caution in patients with diabetes mellitus (may increase blood glucose),May cause hyperuricemia and gout
Hypotension and volume depletion,Electrolyte imbalances (hypokalemia, hyponatremia, hypochloremia),Ototoxicity (especially with rapid IV administration or high doses),Hyperuricemia,Sulfonamide allergy cross-reactivity
Anuria,Hypersensitivity to ethacrynic acid or any component of the formulation,Severe electrolyte depletion (hypokalemia, hyponatremia) until corrected,Concurrent use with other ototoxic drugs (e.g., aminoglycosides) may increase risk
Anuria,Severe electrolyte depletion,Hypersensitivity to sulfonamides or bumetanide (Demadex is a sulfonamide derivative)
Avoid licorice, which can worsen hypokalemia. Limit salt intake as directed. No specific food interactions; maintain a balanced diet.
Avoid excessive licorice intake (glycyrrhizin) as it can exacerbate hypokalemia. Limit sodium-rich foods (processed foods, canned soups) to enhance diuretic effect and control edema. Increase potassium-rich foods (bananas, oranges, potatoes) unless on a potassium-sparing medication. Avoid grapefruit juice as it may affect metabolism.
First trimester: Limited human data; animal studies show no teratogenicity but fetal toxicity at high doses. Second trimester: Theoretical risk of electrolyte imbalances affecting fetal development. Third trimester: Risk of premature ductus arteriosus closure due to prostaglandin inhibition (theoretical), neonatal ototoxicity, and thrombocytopenia.
DEMADEX (torsemide) is a loop diuretic. Human data are limited. In animal studies, high doses caused fetal resorptions and maternal toxicity. First trimester: insufficient human data; avoid unless benefit outweighs risk. Second/third trimester: risk of fetal oligohydramnios, renal impairment, and hypovolemia; use only if clearly needed.
Safety not established. Drug excreted in breast milk; M/P ratio unknown. Avoid breastfeeding or use with caution due to potential for ototoxicity and electrolyte disturbances in the infant.
Torsemide is excreted in breast milk in small amounts; M/P ratio not reported. Due to potential for diuresis, electrolyte imbalance, and allergic reactions in the infant, caution is recommended. Alternative diuretics with more safety data are preferred.
No standard dose adjustment; use lowest effective dose. Monitor for hypokalemia and volume depletion, which may be more pronounced in pregnancy. Consider adjusting dose based on maternal weight and renal function.
Dosing may need adjustment due to increased plasma volume and GFR in pregnancy. Start at lowest effective dose. Monitor diuretic response and electrolyte balance; dose titration may be required. Postpartum, drug elimination may return to prepregnancy kinetics.
Ethacrynic acid is a loop diuretic used for patients with sulfonamide allergy, as it is not a sulfonamide derivative. Monitor for ototoxicity, especially when given with aminoglycosides or in renal impairment. Rapid diuresis may cause hypokalemia, hypomagnesemia, and metabolic alkalosis. Use cautiously in hepatic cirrhosis to avoid electrolyte-induced coma.
DEMADEX (torsemide) is a loop diuretic with high bioavailability (80-100%) and a longer half-life (3-4 hours) than furosemide, allowing once-daily dosing. It is primarily metabolized by CYP2C9, so caution is needed with CYP2C9 inhibitors like amiodarone. Monitor for ototoxicity at high doses or rapid infusion. Hypokalemia risk persists; consider potassium supplementation or aldosterone antagonist. Use cautiously in sulfonamide allergy due to potential cross-sensitivity.
Take exactly as prescribed, usually once or twice daily.,Expect increased urination; take in the morning to avoid nighttime trips.,Weigh yourself daily and report rapid weight gain or loss.,Avoid alcohol and medications that may cause dizziness.,This drug may cause hearing loss or ringing in the ears; report immediately.,Do not take with aspirin or other NSAIDs without doctor approval.,Inform your doctor if you have gout, diabetes, or kidney disease.,Stay adequately hydrated but avoid excessive fluid intake.
Take DEMADEX exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Weigh yourself daily and report sudden weight gain or loss of more than 2-3 pounds in a day.,Avoid alcohol and beverages containing caffeine as they may increase dehydration.,Do not take DEMADEX with licorice (which can worsen hypokalemia) or with high-sodium antacids.,Report signs of hearing loss, ringing in the ears, dizziness, or muscle cramps immediately.,Stand up slowly to prevent dizziness from low blood pressure.,Monitor for signs of dehydration: dry mouth, thirst, infrequent urination.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ETHACRYNIC ACID vs DEMADEX, answered by our medical review team.
ETHACRYNIC ACID is a Loop Diuretic that works by Inhibits sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, potassium, and water. Also inhibits prostaglandin degradation.. DEMADEX is a Loop Diuretic that works by Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ETHACRYNIC ACID and DEMADEX depend on the specific clinical indication. These are both Loop Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ETHACRYNIC ACID is: 50 to 100 mg orally once daily; may increase by 25 to 50 mg increments at intervals of 2 to 3 days up to 400 mg/day. IV: 0.5 to 1 mg/kg slowly (over several minutes); usual initial dose 50 mg.. The standard adult dose of DEMADEX is: Oral: 5-10 mg once daily; may increase to 20 mg once daily if needed. IV: 5-10 mg once daily; may increase to 20 mg once daily if needed. Maximum dose: 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ETHACRYNIC ACID and DEMADEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ETHACRYNIC ACID is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity but fetal toxicity at high doses. Second trimester: Theoretical risk of electrolyte imbalances affecting . DEMADEX is classified as Category C. DEMADEX (torsemide) is a loop diuretic. Human data are limited. In animal studies, high doses caused fetal resorptions and maternal toxicity. First trimester: insufficient human da. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.